Ironwood pharmaceuticals, inc. (IRWD)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Total revenues

439,626

428,413

432,804

367,323

346,214

346,639

310,155

331,294

315,265

298,276

291,527

270,808

260,081

273,957

0

0

0

-

-

111,667

90,763

76,436

43,394

31,408

34,231

22,881

44,830

136,311

141,252

150,245

155,419

71,224

67,882

65,871

42,776

39,746

0

0

0

Cost and expenses:
Cost of revenues

25,071

23,875

34,325

38,435

31,187

32,751

20,272

21,736

21,173

19,097

0

0

0

-

-

-

-

-

-

-

3,379

5,291

4,081

14,996

7,896

7,203

0

0

0

-

-

-

-

-

-

-

-

-

-

Write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments

-

-

0

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

110,873

115,044

100,717

102,324

96,753

101,060

68,884

76,791

90,948

88,145

146,553

147,014

141,352

139,492

128,677

116,981

113,947

108,746

108,601

107,893

101,387

101,890

96,924

94,818

96,769

102,378

108,135

108,572

116,717

113,474

109,425

108,877

96,048

86,093

80,611

77,603

0

0

0

Selling, general and administrative

159,805

172,450

183,128

192,745

209,270

219,676

225,822

237,060

235,081

231,184

230,378

213,591

192,717

173,281

149,580

135,032

131,069

125,247

124,315

122,411

118,755

118,333

116,478

118,207

119,778

123,228

127,782

120,364

109,593

92,538

0

0

0

-

-

-

-

-

-

Amortization of acquired intangible assets

-

-

-

-

-

8,111

11,587

12,325

9,270

6,214

5,951

5,119

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on fair value remeasurement of contingent consideration

-

-

-

0

-

-31,045

-70,274

-37,383

-32,412

-31,310

16,586

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restructuring expenses

300

3,600

4,278

14,578

15,578

14,700

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of intangible assets

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42,074

50,442

46,766

38,705

16,030

0

0

0

-

-

-

-

-

-

Total cost and expenses

289,342

308,290

315,828

462,805

477,950

497,309

422,484

316,486

326,791

313,639

397,977

386,111

349,688

325,827

291,202

262,566

262,654

251,643

263,707

251,607

243,813

245,806

226,377

234,203

241,787

274,883

293,994

281,316

267,211

223,007

191,313

176,342

151,118

132,013

118,051

110,715

0

0

0

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Income (loss) from operations

150,284

120,123

116,976

-95,482

-131,736

-150,670

-112,329

14,808

-11,526

-15,363

-106,450

-115,303

-89,607

-51,870

-51,397

-49,295

-75,989

-102,088

-129,386

-139,940

-153,050

-169,370

-182,983

-202,795

-207,556

-252,002

-249,164

-145,005

-125,959

-72,762

-35,894

-105,118

-83,236

-66,142

-75,275

-70,969

0

0

0

Other (expense) income:
Interest expense

34,230

36,602

39,065

38,090

38,043

37,724

37,344

36,997

36,660

36,370

36,818

37,448

38,229

39,153

39,480

39,736

35,783

31,096

26,375

21,674

21,103

21,166

21,204

21,149

21,164

21,002

15,722

10,471

5,166

59

55

57

61

63

130

158

0

0

0

Interest and investment income

2,903

2,862

3,134

2,982

3,046

2,991

2,773

2,633

2,397

2,111

1,838

1,544

1,343

1,169

974

823

599

443

369

284

278

257

230

200

184

192

205

205

200

197

206

270

351

456

572

656

0

0

0

(Loss) gain on derivatives

-4,410

3,000

-14,190

-5,935

-6,072

-8,700

1,903

-5,915

231

-3,284

912

9,782

7,590

8,146

-5,297

-10,046

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

0

-

-

-

-

-

-

-2,009

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

900

0

0

0

-

-

Other expense, net

-66,150

-61,180

-80,933

-40,946

-41,112

-43,476

-32,668

-40,279

-34,032

-39,552

-36,077

-28,131

-31,305

-29,838

-30,843

-47,131

-46,755

-40,581

-36,893

-20,937

-20,164

-20,248

-20,974

-20,949

-20,980

-20,810

-15,517

-10,266

-4,966

138

151

1,110

1,187

1,293

1,342

501

0

0

0

Net loss before income tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

-

Income tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

-

Net income (loss) from continuing operations

84,134

58,943

-140,738

-185,523

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss from discontinued operations

-

-37,438

-59,966

-85,209

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net income (loss) and comprehensive income

84,134

21,505

-41,877

-236,828

-298,508

-282,368

-254,790

-112,736

-107,580

-116,937

-142,527

-143,434

-120,912

-81,708

-82,240

-96,426

-122,744

-142,669

-166,279

-160,877

-173,214

-189,618

-203,957

-223,744

-228,536

-272,812

-264,681

-155,271

-130,925

-72,624

-35,743

-104,011

-82,052

-64,852

-66,148

-62,651

0

0

0

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net income from discontinued operations attributable to noncontrolling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net income per share from continuing operations - basic and diluted (in dollars per share)

0.02

0.31

0.13

0.08

-0.14

-

-0.99

-0.16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.13

-

Net loss per share from discontinued operations - basic and diluted (in dollars per share)

-

0.00

0.00

0.00

-0.24

-

-0.15

-0.17

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.05

-

Net income (loss) per share - basic and diluted (in dollars per share)

0.02

0.31

0.13

0.08

-0.38

-0.10

-1.14

-0.32

-0.29

0.10

-0.22

-0.30

-0.36

-0.09

-0.23

-0.15

-0.09

-0.09

-0.33

-0.34

-0.24

-0.27

-0.30

-0.44

-0.38

-0.40

-0.51

-0.57

-0.87

-

-

-0.38

-0.34

-

-

-0.19

-0.19

-0.08

-

Weighted average common shares outstanding used in computing net income (loss) per share- basic and diluted:

-

-

156

155

-

610,079

153

152

151

595,525

149

148

147

579,278

145

144

143

285,101

142

142,098

141,278

139,950

139,234

138,315

129,745

241,773

120

113,441

108,073

-

-

107,078

103,751

-

-

-

-

-

-

Continuing operations - basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.18

Basic net income (loss) per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.44

-

-

-

-0.21

-

-

-

-0.18

Continuing operations - diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.18

Diluted net income (loss) per share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.42

-

-

-

-0.21

-

-

-

-0.18

Weighted average shares used in computing net income (loss) per share - basic

158

-

-

-

154

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

107,266

-

-

-

100,174

99,674

99,075

97,925

97,642

Weighted average shares used in computing net income (loss) per share - diluted

159

-

-

-

154

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

114,337

-

-

-

100,174

99,674

99,075

97,925

97,642

Unrealized gain (loss) on short-term investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Other comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Comprehensive income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

Collaborative arrangements revenue
Total revenues

387,945

379,652

358,350

282,020

275,905

272,839

0

0

0

-

-

-

-

263,923

226,070

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue, net
Total revenues

-

-

-

-

-

3,445

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sale of active pharmaceutical ingredient
Total revenues

51,681

48,761

73,975

83,589

67,499

70,355

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-